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ABSTRACT 
 
Liquid chromatography–mass spectrometry (LC–MS) with electrospray (ES) ionization in the positive 
ion mode was applied to drug analysis in forensic toxicology.  Several types of screening and 
confirmation strategies were developed, based essentially on searching of comprehensive MS libraries 
and databases that were created in-house for the purpose. 
 
Two spectral libraries, both containing spectra for approximately 400 drugs, were created.  Spectra for 
the LC–MS/in-source collision-induced dissociation (CID) library were acquired by continuously 
switching between low (25 V) and high (90 V) orifice voltages during the run, and the summed mass 
spectra were added to the library.  A library for liquid chromatography–triple quadrupole mass 
spectrometry (LC–MS/MS) was created by obtaining product ion spectra at a collision energy of 35 
eV, and additionally at 20 eV or 50 eV, if the latter were more informative.   The product ion spectra 
were reproducible in the long-term, based on a four-year experiment. Comparison of two libraries, 
independently created with similar instruments in different laboratories, showed that the libraries were 
fully compatible.  Comparison of spectra obtained with different manufacturers’ instruments suggested 
that after standardization of collision energy and gas pressure, LC–MS/MS spectral libraries are 
suitable for interlaboratory use. 
 
The libraries were utilized in two fully automated methods for selected drug groups, comprising   
screening and confirmation.  Analysis of 16 β-blocking drugs in urine involved two-step MS analysis, 
including a screening step based on monitoring of protonated molecules and a confirmation step based 
on LC–MS/MS product ion spectra.  A method for simultaneous screening and quantitation of 18 
antihistamine drugs in blood involved multiple-reaction monitoring (MRM) for screening and 
quantitation and product ion spectra for confirmation of the drugs.  The antihistamines were identified 
and quantified at concentrations ranging from subtherapeutic to toxic in blood.  A data-dependent 
experiment (DDE) was utilized for automation of both procedures, from starting the sample batch to 
printing of the library search results.   
 
Two different approaches for comprehensive screening of drugs were developed. A method for 
simultaneous screening of 238 drugs in blood was developed using LC–MS/MS with multiple-reaction 
monitoring. Identification was based on RT and the presence of protonated molecule and one 
representative fragment ion.  The method was shown to be sufficiently selective and sensitive to allow 
the majority of the drugs to be detected at therapeutic concentrations.  Another approach was based on 
accurate mass determination with liquid chromatography–time-of-flight mass spectrometry (LC–
MS/TOF), using a target database of monoisotopic masses for 433 drugs.  The method was tentatively 
suitable for rapid screening of drugs in urine even without referral to primary reference standards.
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ABBREVIATIONS 
APCI Atmospheric pressure chemical ionization 
CE Collision energy  
CID Collision-induced dissociation 
DAD Diode array detection 
DDE Data-dependent experiment 
DLI Direct liquid introduction 
EI Electron impact 
ES Electrospray 
GC Gas chromatography 
GC–MS Gas chromatography–mass spectrometry 
IDA Information dependent acquisition 
LC Liquid chromatography (high performance) 
LC–MS Liquid chromatography–mass spectrometry 
LC–MS/MS Liquid chromatography–tandem mass spectrometry  
LLE Liquid-liquid extraction 
LOD Limit of detection 
LOI Limit of identification 
LOQ Limit of quantitation 
MRM Multiple-reaction monitoring 
MS Mass spectrometry 
OPLC Overpressured layer chromatography 
Q-TOF Quadrupole-time-of-flight instrument 
Q-trap Quadrupole-ion trap instrument 
RP Reversed phase 
RSD Relative standard deviation 
RT Retention time 
SPE Solid-phase extraction 
SIM Selected ion monitoring 
TIC Total ion chromatogram 
TLC Thin-layer chromatography 
TOF Time-of-flight 
TS Thermospray 
UV Ultraviolet (spectrometry)
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1.  INTRODUCTION  
 
In forensic and clinical toxicology, demands for analytical laboratories are growing along with the 
rapidly changing drug scene.  The toxicologist must be able to detect and identify drugs and poisons 
that could be abused or cause intoxication and to quantitate them at concentration levels that may vary 
tremendously.  In these types of examination, comprehensiveness and positive identification are of 
primary importance.  Screening methods are needed in toxicology, including areas such as homicides, 
suicidal deaths, traffic accidents, drugs and driving monitoring, work place drug testing, doping 
control, date-rape drugs, poisoned patients etc.   
 
Screening routines should be designed to detect as many drugs as possible within relevant drug classes, 
e.g. antidepressants, neuroleptics, benzodiazepines, analgesics, anaesthetics, β-blockers, antihistamines 
and drugs of abuse.  After therapeutic doses, drugs may be found at low concentrations, from a few 
micrograms to several milligrams per litre in the blood, with lethal concentrations being 10 to 100 
times higher.  Some drugs are metabolized very quickly (e.g. heroin) and are not detectable at all in the 
blood.  Metabolites of the parent drugs may, however, persist for longer periods of time in the urine, 
and therefore urine samples are usually also screened for metabolites.  Most of the toxicologically 
relevant drugs are small stable organic compounds, ranging from 100 to 700 in molecular weight, the 
majority of which are basic, fairly hydrophobic and contain nitrogen.  Various polar (e.g. atenolol), 
nonvolatile (digoxin) and thermally labile (zopiclone) substances require special attention. 
 
Standards for the reliability and accuracy of analytical methods are very high, because the results may 
be used in courts as evidence.  To obtain results with a high level of confidence, the entire procedure 
from sample treatment to detection methods should be sensitive and rugged at the same time.  
Ruggedness is essential, because of the inconstant quality and inestimable contents of post mortem 
samples.  Sensitivity becomes critical not only because the concentration of toxicants may be very low, 
but also because sample volume may often be very limited. 
 
A successful analytical method is a seamless combination of extraction, separation, detection and 
reporting.  The conventional approach has been to extract small groups of compounds separately and 
then to analyse the extracts by target methods dedicated to each compound group.  This is a time-
consuming and tedious procedure.  Therefore, the trend has been towards using universal multistep 
extraction methods that would cover different categories of drugs.  Once such combined extracts with 
chemically different compounds are available, it leads to the next challenge of how to separate and 
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detect them in a single method.  No single technique or instrument is yet available that would cover all 
chemically different drugs specifically, selectively, sensitively, reliably and preferably also 
automatically. 
 
Techniques that are currently used in forensic and clinical toxicology include immunoassays, thin-
layer chromatography (TLC), overpressured layer chromatography (OPLC), liquid chromatography 
with ultraviolet or diode-array detection (LC–UV or LC–DAD) and gas chromatography (GC) with 
different detectors.  Immunoassays are feasible for preliminary screening, but the positive results must 
be confirmed using other techniques.  The benefit of classical TLC is simple and inexpensive 
instrumentation and suitability for many types of compounds, but it lacks specificity, even when 
corrected Rf  values, in situ UV spectra and colour reactions are used for identification.  GC has been 
the method of choice, especially for screening basic drugs using nitrogen-selective detection.  GC 
coupled with mass spectrometry (GC–MS) has been given the status of gold standard in confirmation 
analysis after different screening procedures.  Its high separation power and commercially available 
huge electron impact (EI) spectral libraries are the unquestionable benefits of GC–MS; however, its 
suitability for polar, thermolabile or high-mass molecules is restricted.  Moreover, sample preparation 
often requires complex and time–consuming extraction procedures including derivatization, and 
sensitive screening in the selected ion monitoring (SIM) mode is only possible for 30-40 compounds 
per method.  LC has the benefit of being suitable for several types of compounds, because basically the 
compounds only have to be dissolvable in a suitable solvent.  However, the separation power of LC is 
limited, and a detection method more specific than UV or DAD is needed for reliable identification.  
Since the early 1990s, coupling of LC with MS became common in forensic toxicology, but only 
recently has the scope of LC–MS been widened from target analysis to comprehensive screening and 
confirmation. 
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2.  REVIEW OF THE LITERATURE  
 
2.1  Sample preparation 
 
Drugs are present in blood plasma and inside the haemic cells and should be released before 
extraction.  Hydrophilic drugs are usually free in solution, whereas lipophilic drugs are noncovalently 
bound to proteins or particles.  Noncovalent bonds can be broken by dilution, pH change or organic 
solvents.  Blood analysis is very important in forensic toxicology, because drug concentrations in 
blood represent an acute drug effect and can be used to estimate the probability of intoxication.  
Conversely, many drugs and metabolites are present in urine as conjugates covalently bound to 
glucuronic acid, sulphate or glycine, and must be released prior to extraction, e.g. by enzymatic 
hydrolysis. 
 
The literature available since 1990 concerning the extraction techniques suitable for systematic 
toxicological analysis was reviewed by Drummer1 and Polettini.2 Three different methods have 
commonly been used to isolate drugs from biological material: liquid-liquid extraction (LLE), solid-
phase extraction (SPE) and protein precipitation/dilution.  Precipitation of whole blood or dilution of 
urine e.g. with acetonitrile or methanol, are rapid and simple procedures, but large amounts of matrix 
material are co-extracted and may interfere with the analysis.  Additionally, the analytes may stick into 
the surface of particles during precipitation, which lowers the recovery.  SPE is a commonly used 
extraction method that enables sample preparation in batches and automation of the extraction 
procedure, and generally provides good selectivity and clean extracts.3  Mixed-mode columns 
(reversed phase (RP) + ion exchange) are especially feasible for extraction of a broad range of 
chemically different compounds.  SPE is very suitable for urine samples, which are homogeneous and 
thereby do not cause blockage of the extraction columns.    It can also be used for autopsy blood;4,5 
however, the material may be lumpy and sometimes even decayed, causing blockage of the SPE 
column, which can be decreased by sonication before SPE.6-8  Plasma would be a less complicated 
matrix, but in postmortem samples it cannot be separated from whole blood due to haemolysis. 
Therefore, LLE is more generally suitable for autopsy blood samples.9  In screening methods, 
compounds with different polarities are analysed, and reasonable coverage with LLE can only be 
obtained through separate extraction of acidic and basic compounds.  To shorten the total analysis 
time, the acidic and basic extracts can be combined and subjected simultaneously to MS detection.
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2.2  Liquid chromatography prior to mass spectrometry 
 
The status of LC–MS was reviewed by several authors.10-16 Due to its universality, LC is a very 
suitable separation technique for multicomponent analysis.  The benefit of using LC instead of GC is 
the feasibility of analysing also thermolabile, polar and volatile compounds without time-consuming 
extraction and derivatization procedures.  On the other hand, the separation efficiency is not as good as 
in GC, however, this disadvantage is not critical because MS provides good specificity and selectivity.  
The only special demands are the use of volatile buffers (e.g. ammonium acetate) and low flow rates 
(< 300 µl/min in an ion spray), which allows the liquid to be evaporated in the ion source.  In contrast 
to the first estimations, the chromatographic separation step is important even when a mass 
spectrometer is used as a detector.  Typically, a slow gradient (10 - 30 minutes) and reversed phase 
column (10 to 15 cm) have been used to obtain acceptable separation of various types of compounds in 
a reasonable total analysis time.   
 
2.3  Ionization by electrospray      
 
The first scientific report of charged aerosols generated by electrospray (ES) at atmospheric pressure 
was described by Zeleny in 1917.17  During the 1960s and 1970s, several research groups worked on 
early models of ES and chemical ionization (CI) interfaces for MS, e.g. Dole et al.,18 Tal’Rose et al.,19 
Horning et al.,20 Arpino et al.,21,22 and Iribarne and Thomson.23  One of the earliest combinations of ES 
with MS was introduced by Yamashita and Fenn in 1984.24  Twenty years later, LC–MS techniques 
also became popular in forensic toxicology.  In an overview on interfacing LC with MS, van Bocxlaer 
et al.14 distinguished between three principally different approaches: 1) removal of the mobile phase 
followed by vaporization and ionization of the analytes,  2) direct ionization from the effluent stream 
and 3) nebulization of the effluent followed by chemical ionization or ion evaporation.  For 
nebulization, four different techniques are used: DLI (direct liquid introduction), TS (thermospray), ES 
(electrospray) and APCI (atmospheric pressure chemical ionization).  Recently, APPI (atmospheric 
pressure photoionization) has also been used for ionization.25 Instrumentation for ES and APCI is 
commercially available, and the majority of recent papers concerning practical applications of LC–MS 
in forensic toxicology deal with ES or APCI.  Moreover, ES and APCI were predicted to be of major 
future interest.13,14  In APCI, a discharge electrode is used to ionize solvent molecules, which after 
several ion-molecule reactions, transfer a charge to the analytes.  
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The ES ion source consists of a capillary nebulizer tube to which a voltage is applied.  The sample 
solution is introduced via a syringe pump or LC pump.  When LC is used, the flow rate is usually tens 
or hundreds of microlitres per minute in a normal column (i.d. 1-5 mm), thus requiring splitting of the 
flow down to less than 10 µl/min.  In 1987, Bruins et al.26 described a pneumatically assisted ES, in 
which a drying gas (e.g. nitrogen) is applied to assist droplet formation and evaporation, and splitting 
is not needed. This type of ES is called ionspray, and has been used in most modern toxicological 
applications as well as in the present study. 
 
In an ES ion source, molecules are ionized in the liquid phase and evaporated to the gas phase under 
atmospheric pressure, then introduced into a mass spectrometer.  The formation of gas-phase ions is 
assumed to occur by direct emission of ions from microdroplets during ion evaporation23 or by 
coulombic fission27 or by both ways simultaneously.  According to the ion evaporation theory, solvent 
evaporates from the charged droplets and consequently the droplets diminish in size until finally, at the 
Rayleigh limit, the formation of gas-phase ions occurs directly from the small droplets.  In the 
coulombic fission theory, evaporation of the solvent causes an increase in charge repulsion at the 
surface of the droplets, and the coulombic strain is released by droplet fission.  
 
The response in ES is concentration-sensitive and not mass flow-sensitive, and favours low flow 
rates,28 which enables the use of small-bore columns with high resolution.  ES is also a soft ionization 
technique, and therefore molecules are only slightly, or not at all, fragmented.  Protonated [M+H]+ or 
deprotonated [M-H]- molecules are mainly observed, depending on the polarity of the electric field 
applied to the tip of the capillary needle.  However, some structural information can be obtained, e.g. 
using the so-called in-source collision-induced dissociation (in-source CID) techniques, in which 
molecules are fragmented inside the ion source using increased voltage of the declustering potential 
lens (orifice voltage) (Figure 1).  
 
2.4  LC–MS/in-source CID spectral libraries 
 
GC–MS libraries have been used for the identification of unknown compounds for years.  This has 
been possible because EI spectra are very reproducible, and therefore several huge commercial spectral 
libraries are available that include as many as several hundred thousand compounds.  For example, the 
NIST 02 (National Institute of Standards and Technology, http://sisweb.com) contains EI spectra for 
approximately 147 000 compounds.  The situation is different with single-quadrupole LC–MS, in 
which fragmentation is affected by several parameters because it occurs inside the ion source; thus, 
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common LC–MS libraries have not been established until recently.  Several groups29-34 investigated the 
effect of different variables, such as mobile phase composition, pH, flow rate, analyte concentration, 
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Nebulization 
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Figure 1.  In-source CID fragmentation in an electrospray ion source. 
 
heater gas temperature, ion source dirtiness and needle position.  In addition to the most important 
variable (declustering potential), needle position and heater gas temperature also significantly affect 
the appearance of the spectra, while the other variables have more effect on the intensity of mass 
signals.  The settings of these parameters are not always reproducible, and it has been demonstrated 
that comparison of in-source CID spectra between instruments demands effective tuning of the 
instruments.  Glafenine and haloperidol were suggested as tuning compounds.29-31,35-36  The 
reproducibility of spectra has also been questionable; indeed, poor reproducibility was reported even 
within a single instrument.32
 
Declustering potential (the difference between voltages at the orifice plate and skimmer, Figure 2), 
which mainly affects in-source CID spectra, can be very effectively used to obtain fragmentation, and 
several spectral libraries have been created based on summarizing spectra obtained with and without 
fragmentation (Table 1). These summarized spectra contain both the protonated molecule [M+H]+ and 
its main fragments, and thus a lot of information.  However, in practical work with real samples a 
problem arises from co-eluting compounds, which leads to a summary spectrum of all these 
compounds. This type of unknown multicomponent spectrum cannot be resolved from any library. 
 
Comparisons of spectra between different quadrupole mass spectrometers have been reported both 
with in-source CID spectra and with MS/MS product ion spectra.  In-source CID spectra were shown 
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to contain the same fragments, but significant differences in their relative ion ratios were noted even 
after tuning of the instruments.32-37    
 
2.5  LC–MS/MS product ion spectral libraries 
 
A triple-quadrupole instrument (Figure 2) consists of three quadrupoles in sequence.  A selected mass 
range can be scanned with the identical mass filter quadrupoles Q1 and Q3.   The center quadrupole 
(Q2) is used for fragmentation and is referred to as the collision cell.  The collision energy (CE) is the 
difference in voltages between the collision cell offset and entrance rod (Q0) potential. 
                
                          Collision cell  
           Q1                   Q2                  Q3
                  Figure 2.  Schematic structure of a triple-quadrupole mass spectrometer (Sciex). 
 
The appearance of an MS/MS spectrum in triple-quadrupole instruments is not dependent on the 
design of the ion source, because fragmentation occurs after it inside the second quadrupole, i.e. in the 
collision cell (Figure 3, Q2), but the efficiency of ionization and the transfer of ions into the gas phase 
affects the intensity of the entire spectrum.  Once a precursor ion is selected in the first quadrupole 
(Q1) and introduced into the collision cell, the fragmentation is affected by CE and collision gas 
pressure.  Both these parameters can be exactly and reproducibly adjusted.  The earliest standard 
operation protocols for acquiring MS/MS spectra with triple quadrupoles were established twenty 
years ago,38 and later it was shown that with fixed settings it is possible to create spectral libraries that 
are instrument-independent.34  Recently, this was also shown to be possible with modern LC–MS/MS 
triple-quadrupole instruments.40
 
The question of using peak intensity ratios as an identification criterion has been under discussion 
among research groups developing spectral libraries.  While ion ratios vary depending on the 
ionization and fragmentation techniques used, a new approach was developed to ignore their effect on 
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library search results: a library was created by putting the m/z values of the fragments in the library at 
100% or 50% intensity only, which was chosen depending on the signal peak area counts.  Using this 
simplified procedure, MS/MS spectra obtained with different triple-quadrupole instruments and with 
an ion trap mass spectrometer, were fully comparable.41,42              
                                        Q1    Q2                       Q3 
 
 
 
 
 
                                Precursor ion        Fragmentation       Product ion scan 
                                filtering 
        
Figure 3.  Acquisition of an MS/MS product ion spectrum in a triple-quadrupole mass spectrometer.  
 
Several laboratories have developed LC–MS/in-source CID and LC–MS/MS spectral libraries with 
quadrupole instruments for in-house use, but few of these have been published although some are 
currently available on the Internet.  Some of the first published spectral libraries are summarized and 
described briefly in Table 1.   
 
Table 1. Some of the first published LC–MS spectral libraries. The number of compounds may have 
been updated since establishment of the library. 
Instrument  Fragmentation Compound  Approx. number  Reference 
Type Type Type  of Compounds   
Single quadrupole In-source CID Drugs Not available Josephs, 1995 43
Single quadrupole In-source CID Drugs, toxicants 600 Marquet, 1998 44
Single quadrupole In-source CID Pesticides,explosives 90 Schreiber, 2000 31
Single quadrupole In-source CID Drugs 400 Weinmann, 1999 29
Single quadrupole In-source CID Pesticides, drugs 38 Hough, 2000 34
Triple quadrupole MS/MS Pesticides 73 Slobodnik, 1996 45
Triple quadrupole MS/MS Pesticides 115 Kienhuis, 2000 41
Triple quadrupole MS/MS Drugs 400 Weinmann, 2000 40
Ion trap MS/MS Miscellaneous Not available Sander, 200046
Ion trap MS/MS Drugs Not available  Fitzgerald, 1999 47
Ion trap MS/MS Natural products Not available Sanders, 200048
Ion trap MS/MS Miscellaneous 600  Baumann, 2000 49
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The number of compounds mentioned in Table 1 are those originally reported and have probably 
increased, since these libraries are updated continuously.  As can be concluded from the variety of 
libraries, cooperation in combining existing libraries or creating new and comprehensive ones will not 
be easy, but would be beneficial for all laboratories.  Quadrupole-ion trap (Q-trap) libraries have also 
been created, and recently it was shown that a library, set up with a triple quadrupole instrument, can 
be transferred to a linear Q-trap mass spectrometer.50  
 
Long-term reproducibility of spectra is a critical issue, because continuity and high confidence level 
are demanded in the identification of unknowns in forensic cases.  With the exception of one study,32 
good reproducibility over three to eight months was reported for LC–MS/in-source CID spectra33,34 
and over 30 months for LC–MS/MS spectra.40  However, taking into account the huge amount of 
labour needed to create a large spectral library, reproducibility should be ensured for years, as has been 
established for GC–MS spectral libraries.  
 
2.6  Methods in toxicological screening  
 
Several strategies for screening drugs from forensic samples with LC–MS have been proposed in the 
literature.  Identification has been based on single quadrupole, triple quadrupole, TOF, Q-TOF or Q-
trap techniques.  Prescreening (or survey scanning) is a critical step.  With single quadrupoles, full 
scan or SIM can be used, and with triple quadrupoles multiple-reaction monitoring (MRM) is also 
possible.  The various modes of operation of quadrupole instruments are illustrated in Figures 4-6. 
 
                                       Q1 
 
 
 
 
       Figure 4.  Full scan mode of a single quadrupole mass spectrometer.      
                                           
                                        Q1 
 
 
           
   Figure 5.  Selected ion monitoring mode of a single quadrupole mass spectrometer.  
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                                       Q1                      Q2                       Q3 
 
 
 
   Figure 6.  Multiple-reaction monitoring mode of a triple-quadrupole mass spectrometer.           
 
The first “general unknown” procedure using LC–MS/in-source CID was presented by Marquet et al. 
1998,44 and was later developed further by the same authors.16,30,51  The method included LC-reversed 
phase chromatographic separation and detection by a single mass spectrometer with ionspray interface 
and using the in-source CID fragmentation mode.  Four separate spectra were generated simultaneously, 
two positive and two negative spectra at low (weak fragmentation) and at high (extensive 
fragmentation) orifice voltage.  After acquisition, the low- and high-energy spectra were summed at 
both polarities, and these two reconstructed spectra were searched against positive and negative mass 
spectral libraries.   Similar type of methods were also presented by others.29,52,53  The benefit of using 
in-source CID is that while acquisition is performed in full-scan mode, it is not restricted to previously 
selected compounds.  The moderate price of single mass spectrometers makes them an attractive choice 
for routine laboratories.  The disadvantage, however, is that co-eluting compounds result in interfering 
spectra, making them unsearchable from the libraries of pure compounds.   It has also not been possible 
to reproduce these spectra without extensive tuning of the instrument, and differences in fragmentation 
degree between separate instruments were reported.35  One additional difficulty has been the detection 
of small peaks from the background; however, a new data-handling procedure was recently developed 
to overcome this problem.51  
 
Another screening strategy, based on monitoring of selected ions in a broad scope, was first presented 
by Fillion et al. 1995.54   The method was developed for 189 pesticide residue compounds from foods 
using GC–MS/SIM, but this strategy was also applicable to LC–MS/MS/MRM with certain 
modifications.  Two injections in selective-ion mode were needed to cover all compounds, and the 
criteria for a positive identification were correct retention time (RT) and ion ratio of the target ion to at 
least one qualifier ion. During the first injection, the chromatographic run was split into 35 time 
windows and the second injection into 20 time windows.  Several authors applied this method to LC–
MS/MS to analyse a limited number of drugs from biological samples,55-58 but the results of only one 
broad screening method have been so far published.59  There are several benefits of using MS/MS 
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instead of single MS/in-source CID in screening: higher sensitivity, better specificity because the 
fragments originate only from the selected precursor ion, possibility of linking product ion scanning and 
library searching for confirmation of the identity of the drugs and the option of including quantification 
in the automatic procedure.  On the other hand, one weak point is that no matter how many compounds 
the MRM procedure covers, it never constitutes “general unknown” screening because the compounds 
monitored are selected in advance.  Moreover, the scanning speed of the instrument may set a limitation 
on the number of compounds that can be included in the method.  The high price of instrumentation 
may also restrict its applicability.  Very recently it was reported that specificity of a triple quadrupole 
can be remarkably increased using enhanced resolution, with the mass peak full width at half maximum 
height (fwhm) set at 0.1 Da, which improves mass accuracy from the conventional 0.7 Da to as high as 
0.003 Da.60  This feature has so far been applied only in metabolite identification, but it would be an 
attractive enhancement for broad screening of drugs with LC–MS/MS/MRM.   
 
Time-of-flight (TOF) mass spectrometry is an alternative choice for multicomponent drug analysis of 
biological samples.  In single-MS time-of flight instruments (LC–MS/TOF) (Figure 7), quadrupoles 
focus the ion beam on the TOF analyser, which is positioned perpendicularly, and ions are pulsed into 
the flight tube by applying voltage.  The ions separate according to their m/z values, high-mass ions 
having longer flight times.   
 
                    Figure 7.  Schematic structure of a single-MS time-of-flight mass spectrometer (Applied                  
                                      Biosystems). 
 
LC–MS/TOF provides relatively high mass accuracy (~5 ppm) and reasonable resolution (5000-10000 
fwhm) at moderate cost, and has been used in combinatorial chemistry and in analysis of drugs and their 
metabolites.61-63  An obvious benefit of TOF mass spectrometers is that they acquire the entire mass 
spectrum simultaneously instead of scanning at preset steps.  Any compound of interest can be extracted 
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after acquisition from the original run without the need for re-extracting and reinjecting the sample.  
This is beneficial when the sample amount is limited or when there is no sample left for further studies.  
Acquiring the entire mass spectrum is an important feature when very large numbers of compounds are 
screened.  In such applications, maintaining hundreds of reference compounds is very expensive and 
laborious.  Even though LC–MS/TOF instruments provide accurate molecular weight, screening 
methods using LC–MS/TOF instruments need very good chromatographic separation, because co-
eluting peaks, as well as unintentional in-source CID fragmentation, lead to a mixture of mass peaks of 
unknown origin because the precursor ion cannot be specifically selected.   Another drawback of TOF 
instruments is that they are not as reliable in quantification as quadrupole instruments.   
 
Techniques involving tandem-MS quadrupole-time-of-flight (LC–MS/MS/Q-TOF) also provide 
structural information.  Few studies are available that describe broad screening procedures performed 
with an LC–MS/MS/Q-TOF instrument64-66 although sophisticated methods including screening and 
confirmation in a single run, can be developed.  In one of these methods,65 the first step was a survey 
scan of the desired mass range with single MS.  All masses exceeding the preset threshold of intensity 
were then automatically selected for precursor ions to acquire the product ion scan with LC–MS/MS/Q-
TOF.  The product ion scan was then acquired with different collision energies, because the most 
favourable fragmentation conditions are not known in advance.  Based on these accurate masses, the 
elemental composition of specific peaks was calculated and searched against the Merck Index or 
laboratory’s own list of relevant compounds and their accurate masses.  Finally, the product ion spectra 
obtained were searched against an in-house spectral library.  It was also possible to include automatic 
quantitation in the procedure, based on the accurate mass of the precursor ion.65  LC–MS/MS/Q-TOF 
screening methods have higher selectivity, sensitivity and reliability compared with the traditional GC–
MS and LC–MS methods.  However, one limiting factor is still the ion source, because none of the 
available sources is universal.  From the practical point of view, maintaining mass accuracy at high 
level demands continuous calibration and stable external temperature conditions.  The high price of 
instrumentation and complexity of the method can also be obstacles preventing this technique from 
becoming a routine application in forensic laboratories. 
 
Liquid chromatography coupled with ion trap mass spectrometry (LC–MS/Q-trap) was used in forensic 
toxicology to identify a wide range of basic drugs from urine samples by Fitzgerald et al. in 199947 and 
was recently also applied to broad screening of drugs.50,68  The mass accuracy in an LC–MS/Q-trap 
instrument (~20 ppm for pure compounds at m/z < 500 Da) is much better than in conventional triple 
quadrupoles  (fwhm = 0.7 Da), but not as good as that of LC–MS/TOF and LC–MS/MS/Q-TOF (~5 
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ppm).  In these two LC–MS/Q-trap screening methods,50,68 the survey scan is performed in MRM mode 
or in enhanced-resolution SIM mode followed by the product ion scan automatically started by 
information dependent acquisition (IDA).  Product ion spectra were acquired at three preselected 
collision energies in positive mode50 or at two energies in positive and negative ion mode.68 The spectra 
were then searched against a correspondingly created mass spectral library.  Both of these preliminary 
methods showed a high potential for use of ion traps in analytical toxicology.  The enhanced mass 
accuracy and better sensitivity obtained at no increase in cost compared with quadrupoles makes LC–
MS/Q-trap an interesting new alternative for forensic screening. 
 
2.7 Quantitation in LC–MS/MS/MRM   
 
LC–MS provides the specificity and sensitivity demanded for an accurate quantitation method for a 
wide range of compounds.  LC–MS/MS with multiple-reaction monitoring (MRM) also provides 
quantitation of such substances that are not chromatographically separated, because it can be used to 
filter the interfering ions twice, both in the first and in the third quadrupole.  The procedure very 
effectively cleans the chromatogram, and therefore integration of peak areas is accurate.  However, the 
co-eluting interfering substances from the matrix do not exit the system but become “invisible”.  
Therefore, ion suppression may occur even though it is not seen in any way in the chromatograms.  Ion 
suppression is caused by compounds in the sample matrix that prevent analytes from reaching the 
surface of the droplets during the ion-evaporation process. On the other hand, part of the analytes may 
also precipitate during solvent evaporation or remain unevaporated and thereby never reach the mass 
spectrometer.  In addition, if the protons in the eluent are more attracted by the matrix, then some of the 
analytes will not be ionized and will be drawn out of the interface by the vacuum.67  In these situations, 
suppression of the analytes leads to too low concentrations.  Errors in the results caused by ion 
suppression are sample-dependent and incidental, and quantitation becomes unreliable.  However, the 
standard addition procedure in calibration would diminish the problem, but this is not possible during 
screening.  It also requires substantial amounts of sample, which is often a limitation in forensic cases.  
Therefore, in applications for biological matrices, thorough validation should contain spike tests for a 
wide variety of authentic samples, including high and low spike levels to estimate the extent of 
suppression.  In several applications for combinatorial chemistry, fast chromatography (“high 
throughput”) has been suggested, but this includes the obvious risk of ion suppression, which has been 
demonstrated to appear mostly during the LC-front peak. Therefore, using an efficient LC gradient 
reduces suppression by separating the analytes from the LC-front peak and from other matrix-related 
peaks, which may cause suppression later during the run.69
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  3.  AIMS OF THE STUDY 
 
The purpose of the present study was to develop library search-based LC–MS techniques for drug 
screening and confirmation in forensic toxicology.  The specific aims were the following: 
 
- to create LC–MS/in-source CID and LC–MS/MS spectral libraries for toxicologically relevant drugs 
(I) 
  
- to test the suitability of different modes of operation for screening and confirmation of drugs from 
urine samples, using β-blocking drugs as a sample drug group (I) 
 
- to combine screening and quantification of drugs in blood in a simultaneous and automated procedure, 
using antihistamines as a sample drug group (II) 
 
- to evaluate the long-term reproducibility of MS/MS product ion spectra and to investigate the 
universal applicability of MS/MS spectral libraries obtained with the same and with different 
manufacturers’ triple-quadrupole instruments (III) 
 
- to develop a broad-scale MRM screening method for drugs in blood samples (IV) 
 
- to investigate a screening approach for drugs and their metabolites in urine by accurate mass without 
the use of reference compounds (V) 
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4.  EXPERIMENTAL 
 
Only the major experimental features are described in this section.  More detailed descriptions can be 
found in the original publications I – V. 
 
4.1  Standards and reagents 
 
The test substances obtained from various pharmaceutical companies were of pharmaceutical purity. All 
solvents were of HPLC grade.  Acetonitrile and methanol were purchased from Rathburn (Walkerburn, 
UK), ammonium acetate (p.a.), formic acid (p.a.), dichloromethane, isopropanol and 
tris(hydroxymethyl)-aminomethane (Tris, p.a.) from Merck (Darmstadt, Germany), and butyl acetate 
from Aldrich (Steimheim, Germany).  Purified water was generated with an Alpha-Q water purification 
system from Millipore (Bedford, MA, USA).   
 
For comparison of LC–MS/MS product ion spectra, 30 test substances were selected based on their 
ability to produce several fragments at collision energies of 20, 35 or 50 eV.  Amitriptyline was used for 
standardization of the MS/MS fragmentation conditions, due to its extensive fragmentation pattern at all 
three collision energy levels (III).  Accurate mass calibration of the TOF instrument was performed 
with Jeffamine D-230® (V), which was obtained from Fluka (Buchs, Switzerland). 
 
4.2  Samples 
 
Bovine blood (II, IV) or urine from laboratory personnel (I, V) were used for standard spikes.  
Authentic autopsy samples were used for testing the applicability of methods, e.g. sample behaviour 
during extraction steps, matrix effects and repeatability. 
 
4.3  Instrumentation 
 
LC separation was carried out with Perkin-Elmer Series 200 LC–MS pumps and autosampler using a 
vacuum degasser (I, II, IV).  A Genesis C18 column (100 mm x 2.1 mm i.d., particle size 4 µm;  Jones 
Chromatography, Hengoed, UK) was used for separation, and a Purospher RP-18 LiChroCart 4-4 (40 
mm, particle size 4 µm; Merck) was employed as a guard column.  LC separation in the LC–MS/TOF 
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experiments was performed with an Agilent HP1100 binary pump system and autosampler, equipped 
with a 10-port switching valve for introducing the calibration standard (V).   The separation column was 
a Luna C18 (50 x 2.0 mm i.d., particle size 5 µm; Phenomenex, Torrance, CA, USA). 
 
Mass spectrometry was performed using a PE Sciex API 365 triple stage quadrupole instrument (MSD-
Sciex; Concord, ON, Canada) equipped with a PE Sciex Turbo Ion Spray ion source (I, II, IV).    Three 
other triple quadrupoles were also used in the mass spectral library comparisons; one was an identical 
API 365 from Sciex and the other two were both Micromass Quattro triple quadrupoles (Manchester, 
UK) equipped with ion spray interfaces (III).  Mariner API-TOF mass spectrometer (Applied 
Biosystems, Framingham, MA, USA) equipped with a PE Sciex Turbo Ion Spray interface was used 
(V) in the LC-MS/TOF measurements.  
 
4.4  Methods 
 
4.4.1  Extraction  
 
Diverse extraction methods were used for the urine and blood samples.  The urine samples were 
extracted using SPE with C18 mixed-mode separation columns (Isolute Confirm HCX mixed mode, 
International Sorbent Technology (IST), Hengoed, UK).  For blood samples, two-step LLE was used in 
which the basic drugs were first extracted at pH 11 with butyl acetate, followed by a second extraction 
of the acidic compounds at pH 3 with dichloromethane:isopropanol (95:5).  Finally, the two extracts 
were combined prior to LC separation.  Detailed descriptions for SPE and LLE are given elsewhere (I, 
II). 
 
4.4.2  Liquid chromatography 
 
In all studies, chromatographic separation was performed using a gradient run.  The mobile phase 
consisted of acetonitrile as the organic solvent and an aqueous solution of ammonium acetate (10 mmol, 
0.1% formic acid, pH 3.2) as a buffer, and the total flow was 200 µl/min.  In studies in which only a 
limited number of compounds (16 (I) and 18 (II)) were analysed, the gradient was adjusted to resolve 
most of the compounds from each other.   
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Separation of all components was not possible in screening methods in which hundreds of different 
compounds were analysed, and the main objects were to obtain reasonable retention and as good a peak 
shape as possible for all compounds (IV, V). As a compromise, the following linear gradient was used 
with the Genesis C18 column: CH3CN from 20% to 100% in 10 min with a flow rate of 200 µl/min (IV).  
The total run time was 18 min including a 5-min equilibrium time at the beginning and 3 min for 
cleaning of the column with 100% CH3CN at the end. The gradient was also linear with the Luna C18 
column, and the CH3CN level rose from 5% to 95% in 10 min, but with a flow rate of 400 µl/min (V). 
 
4.4.3  Mass spectrometry 
 
MS was used in I and V, and MS/MS in II, III, and IV.  In the MS/MS mode, a protonated molecule 
was selected as the precursor ion.  For the halogenated compounds, the most abundant isotope (the 
monoisotopic mass) was selected.  All mass spectrometric experiments were performed only in the 
positive ionization mode.   
 
SIM was used for prescreening of β-blocking drugs (I).   The declustering potential (orifice) was set at 
40 V, and the protonated molecules [M+H]+ were monitored with dwell times of 250 ms.  Any matches 
to previously defined RTs and masses of the β-blocking drugs were then subjected to confirmation 
analyses in an automatic data-dependent experiment (DDE).  Confirmation was performed in an 
automatic library search of the resulting product ion spectra against a previously created LC–MS/MS 
spectral library containing 400 compounds. 
 
MRM was applied for prescreening and quantification of antihistamines (II); the ion transitions were 
monitored at a 200-ms dwell time.  The MRM survey scan was automatically followed by a 
confirmation analysis that was initiated with DDE in a manner similar to that used in the method for β-
blocking drugs.  Identification was based on the LC–MS/MS product ion spectra obtained at a collision 
energy of 35 eV and searched against the MS/MS spectral library (II).  
 
In the multicomponent screening method for drugs in blood (IV), all 238 transitions were monitored 
during a single chromatographic time period, but in three consecutive experiments with different 
collision energies (20, 35 and 50 eV).  The appropriate collision energy and monitored ions were 
individually selected for all compounds to achieve the best obtainable specificity and sensitivity.  
However, the choice of collision energy was limited to 20, 35 or 50 eV, because the MS/MS spectral 
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library was created using these values.   The shortest reasonable dwell time (25 ms) and total cycle time 
(6 s) were used.  The positive result was based on correct precursor ion, specific fragment ion and RT of 
the analyte.   
 
LC–MS/TOF was used in the broad screening of drugs from urine samples (V).  Resolution (at least 
5000) and mass accuracy (5 ppm) were optimized daily with three masses of the polymeric material 
Jeffamine D-230®.  Jeffamine was also used for exact mass calibration of each sample by injecting it 
through a switching valve just before each sample injection.  The entire mass spectrum from m/z 100-
750 was acquired and stored with acquisition time of 2 s per spectrum. The compounds were identified 
without reference compounds by comparing the accurate mass of the peaks with the previously compiled 
list of exact masses of toxicologically interesting compounds and their metabolites and also by the 
metabolic pattern found in the urine samples. 
 
Studies of long-term reproducibility of LC–MS/MS product ion spectra and compatibility of spectra 
obtained with different manufacturers’ instruments (III) were performed by acquiring product ion 
spectra of 30 test substances at low (20 or 15 eV), medium (35 or 30 eV) and high (50 or 45 eV) 
collision energies, depending on the instrument.  Standardization of the fragmentation conditions 
(collision energy and collision gas pressure) of different instruments was performed by visual 
comparison of the spectra obtained for amitriptyline, which produced extensive fragmentation patterns 
at all three collision energy levels. 
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5.  RESULTS 
 
5.1  Automated screening and confirmation 
 
In routine forensic analysis, all positive findings from screening procedures must be confirmed.  With 
quadrupole mass spectrometers, this can be based on library searching of LC–MS/in-source CID or LC–
MS/MS spectra.  This presumes the existence of spectral libraries, although no commercial libraries are 
currently available for LC–MS spectra.  Therefore, two in-house libraries were created, for LC–MS/in-
source CID and LC–MS/MS spectra, each containing 400 compounds (I).  The in-source CID spectra 
were acquired by switching between low (25 V) and high (90 V) orifice voltages, and these two spectra 
were summed.  While the low-voltage spectrum was dominated by the protonated molecule [M+H]+ and 
the high-voltage spectrum by fragment ions, their summed spectrum was very informative.  The LC–
MS/MS product ion spectra were obtained at three different collision energies (20, 35 and 50 eV).  For 
many compounds, spectra obtained with 20 eV contained only the protonated molecule, and even 
though it was very intensive the spectrum was not specific enough for identification.  On the other hand, 
at 50 eV many compounds were too extensively fragmented and contained many small fragments at low 
intensity, and these spectra likewise were not suitable for identification.  Therefore, the 35-eV spectra 
were added to the library of all compounds, as were the 20-eV or 50-eV spectra for those compounds 
for which the 35-eV spectra did not contain enough fragments at adequate intensity.  The LC–MS/MS 
spectral library thus contains approximately 530 spectra.  The difference between in-source CID and 
MS/MS spectra is demonstrated in Figure 8.  The MS/MS spectra were more reliable in cases of co-
eluting compounds, because co-elution resulted in mixed spectra that were not recognized in the LC–
MS/in-source CID spectral library. 
 
A fully automatic screening and confirmation procedure was developed for 16 β-blocking drugs in urine 
samples (I).  SPE followed by a 2-step gradient run was used for extraction and chromatographic 
separation.  The survey scan was performed using LC/MS/SIM, and a positive result was based on the 
correct protonated molecule and RT.  The confirmation step was carried out in an automatic second 
injection during which the product ion spectra for all findings were acquired in the MS/MS mode.  An 
application program was used to create the acquisition methods for the confirmation run.  This program 
automatically split the chromatographic run into time periods corresponding to the RTs of the findings.  
A maximum of five product ion spectra were monitored during the same time period, otherwise a third 
injection was done for the other compounds appearing at the same time window; this procedure ensured 
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sufficient sensitivity. The spectra obtained were then automatically searched against the in-house 
spectral library, and the search results were also reported automatically.  The method developed was  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Comparison of the mass spectra for propranolol.  Upper trace: LC–MS/in-source CID spectra 
(summed spectra acquired at 25- and 90-V orifice voltages).  Lower traces: LC–MS/MS spectra at three 
collision energy levels. 
 
sufficiently sensitive to identify β-blocking drugs in urine at the levels expected after therapeutic doses, 
except for pindolol, for which the limit of identification (LOI) based on the product ion spectra (1.2 
mg/l) remained 10 times higher than the therapeutic range in blood (0.02 – 0.15 mg/l).  Application of 
DDE for automation of the screening and confirmation procedure, from the start of the sample batch to 
the summary report of the library search results, was the main target of the study.  In this method, 
automation was carried out with an Apple Scripting application program (Auto MS/MS Builder, Perkin-
Elmer Sciex).   
 
Another application of the DDE was developed for screening and quantitation of 18 antihistamines from 
blood (II). LLE was applied because whole-blood samples may cause blockage of SPE columns. The 
antihistamines are a group of chemically different compounds, and therefore both basic and acidic 
extraction steps were included.  Mass spectrometric analysis was performed using MRM for the survey 
scan, and any matches to a previously defined list of RTs, protonated molecules and major fragment 
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ions were confirmed using product ion spectra in an automatically initiated second run.  Quantitation 
was based on the MRM data obtained during the survey scan. 
 
The extraction recovery varied widely between compounds: for basic drugs from 43% to 137%, and for 
acidic drugs from 23% to 66%.  However, the recovery percentage itself is not essential, but in practical 
work good repeatability and high sensitivity are.  For all antihistamines, the intra-assay precision varied 
from 3% to 9%, and the limits of quantification (LOQs) were between 0.0005 and 0.01 mg/l, far below 
the average maximum concentrations occurring after therapeutic doses of these drugs.  The results 
indicated that the method is sufficiently reproducible and sensitive to be used for quantitation of 
antihistamines.  Identification by product ion spectra was included in the method by DDE and the 
automatic library search application script.  The identity of a drug was considered confirmed when the 
spectral fit was 70% or higher.  The LOIs were not as low as the LOQs (mainly between 0.001 and 0.07 
mg/l), but were low enough to confirm the drugs at higher therapeutic ranges in blood, except for 
clemastine.  The validation results of the method are summarized in Table 2.  Inaccuracy was expressed 
as the maximum bias of the results when two persons performed the analysis on different days during a 
single week.   
 
Table 2.  Validation data for the identification and quantitation of antihistamine drugs in blood samples 
using LC–MS/MS. LOQ = limit of quantitation, LOI = limit of identification  
Compound LOQ, mg/l 
by MRM 
LOI, mg/l 
by MS/MS spectra 
Precision
% 
Inaccuracy 
% 
Recovery 
% 
Acrivastine 0.001 0.005 7 29 35 
Astemizole 0.002 0.001 3 20 39 
Brompheniramin 0.0005 0.007 3 12 43 
Carbinoxamine 0.002 0.002 3 6 37 
Cetirizine 0.001 0.005 9 35 24 
Chlorpheniramin 0.001 0.002 3 8 38 
Cinnarizine 0.005 0.003 6 16 85 
Clemastine 0.0005 0.015 6 15 91 
Cyclizine 0.005 0.005 5 5 137 
Diphenhydramin 0.005 0.015 4 12 65 
Ebastine 0.01 0.001 5 20 62 
Fexofenadine 0.0005 0.005 8 15 NE 
Hydroxyzine 0.001 0.001 3 8 53 
Levocabastine 0.0005 0.003 6 39 66 
Loratadine 0.002 0.001 3 10 91 
Mizolastine 0.002 0.002 3 10 43 
Prometazin 0.008 0.007 3 8 32 
Terfenadine 0.003 0.001 7 12 65 
NE = not examined 
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5.2  Quantitative analysis 
 
The calibration curves of the antihistamines were nonlinear along a broad concentration range.  Various 
regressions for the same calibration points were tested, and the effect on correlation is illustrated in 
Figures 9-11 (VI).  The best accuracy was achieved for low concentration points by excluding the 
highest calibration points and using linear regression forced through zero (Figure 10).  Quadratic 
regression including all calibration points was applied only when a broad concentration range was 
needed (Figure 10).   
 
 
Figure 9.  Linear calibration curve of carbinoxamine at concentration range 0.001-0.1 mg/l. 
Correlation coefficient = 0.9847. 
 
 
 
Figure 10.  Linear calibration curve of carbinoxamine at concentration range 0.001-0.1 mg/l. 
The highest calibration point is excluded and the curve is forced through zero. Correlation 
coefficient = 0.9993. 
 
 
 
Figure 11.  Quadratic calibration curve of carbinoxamine at concentration range 0.001-0.1 
mg/l. Correlation coefficient = 0.9996. 
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Bending of the calibration curves was assumed to be due to ion suppression caused by high 
concentration of the analytes or by the matrix. Therefore, the possible presence of matrix-related ion 
suppression was estimated by spiking the antihistamines to authentic autopsy blood samples, including 
decayed and lumpy samples.  Comparison of the relative standard deviation (RSD) within and between 
samples showed that the difference was only approximately 10% (Table 3).  
 
Table 3. Estimation of ion suppression effect by calculating relative standard deviation (RSD) within 
and between 15 authentic autopsy samples spiked with 0.025 and 0.05 mg/l antihistamine mixture.  
Compound RSD-% 
  
Within sample 
n = 15 
Between samples 
n = 15 
Acrivastine 8.9 12.9
Astemizol 11.9 22.6
Bromopheniramine 4.4 10.7
Carbinoxamine 3.3 9.5
Cetirizine 9.0 19.0
Cinnarizine 19.1 37.6
Clemastine 18.8 22.2
Chlorpheniramine 3.6 9.4
Cyclizine 10.9 20.9
Diphenhydramine 10.2 24.9
Ebastine 13.6 28.2
Hydroxyzine 7.1 24.1
Levocabastine 18.2 25.2
Loratadine 13.0 23.6
Mizolastine 8.8 25.8
Prometazine 10.6 21.6
Terfenadine 16.5 21.9
 
Therefore, it was concluded that the nonlinearity of the calibration curves at high concentrations in our 
study was not caused by the matrix, but by too high a spiking concentration.  In such circumstances, the 
dynamic range ends and part of the analyte ions remain inside the droplets and will not get into the gas 
phase. 
 
5.3  Reproducibility of MS/MS spectral library search 
 
The LC–MS/MS product ion spectra of 30 test substances were acquired using three different collision 
energy levels, and searched against the in-house library containing 400 compounds that was created 
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four years earlier.  Very good Fit percentages (86-98%) were obtained for the newly acquired spectra of 
all compounds at all tested fragmentation conditions, demonstrating good long-term reproducibility.   
 
To examine the interlaboratory reproducibility, comparison of spectra between two similar instruments 
from the same manufacturer was carried out.  The libraries were independently created and both 
contained spectra of approximately 400 drugs.  In these libraries, the spectra were acquired at three or 
four collision energy levels, two of which were the same (20 eV and 50 eV), and could be compared 
directly.  Thirty test substances were selected from one library and searched against the other. The Fit 
percentages varied between 93% and 95%.  At medium energy, one library had spectra at 35 eV and the 
other at 30 and 40 eV.  Comparison showed that the spectra at 35 eV were closer to those at 30 eV than 
at 40 eV.  Even though the collision energies were not exactly the same, Fit percentages were as good 
as 82–89%.   
 
To examine the reproducibility of spectra acquired with different manufacturers’ triple-quadrupole 
instruments, standardization of fragmentation conditions was needed prior to spectral comparison.  
Amitriptyline was suitable for this purpose, because it produced product ion spectra with several 
fragments at all applied CEs.  After standardization, 30 test substances were acquired with two 
instruments from two manufacturers, and the product ion spectra obtained were searched against the 
reference library.  A graphic presentation of the results is shown in Figure 12.   
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Figure 12.  Comparison of spectra obtained with different manufacturers’ triple quadrupoles.  
Similarity is expressed as Fit percentage against the reference library of the Sciex A instrument.  
 
  35 
 
As can be seen, the similarity of spectra obtained with different manufacturers’ instruments, was 
generally very good (Fit between 80% and 85%). The only obtrusively low value for dipyridamole 
(45%) was regarded as random error occurring during handling or processing of the sample, because no 
special difficulties have been encountered during previous use of this compound. 
 
5.4  Comprehensive screening by multiple-reaction monitoring 
 
A comprehensive screening for drugs in blood was developed for LC–MS/MS operating in the MRM 
mode.   This approach was successfully enlarged to include 238 drugs.  It was demonstrated that as 
short a dwell time as 25 ms was sufficient to obtain an adequate signal-to-noise ratio for reliable 
detection of compounds at their therapeutic levels.   The short dwell time enabled monitoring of a large 
number of compounds during a single chromatographic run without splitting it into time periods.  
Positive identification was based on three criteria: correct precursor ion, fragment ion and RT.  
Additionally, the signal-to-noise ratio at the limit of detection (LOD) was required to be at least three,  
data points across the chromatographic peak at least four and areas for internal standards above the  
limits given to show that extraction was successful.  The LOD values were determined for all 238 drugs 
and were within the therapeutic ranges of these drugs (Table 4), including such acidic/neutral 
compounds (e.g. paracetamol and theophylline) that are not very sensitive in positive ion mode. 
 
The suitability and coverage of the method can be seen from Table 4, which presents typical 
therapeutic ranges, LODs, RTs, monitored fragment ions and collision energies for 80 drugs commonly 
found in autopsy cases in Finland between 2000 and 2003.  Screening for only these compounds would 
cover 87% of all findings obtained with all other methods during these years (GC, GC–MS, TLC and 
OPLC).  Comparison of 71 authentic autopsy blood samples revealed that 92% of the findings were 
consistent with those obtained with GC, GC–MS or TLC/OPLC.  Of a total of 256 positive findings, 
only 18 could not be verified by any other method or from other sample material.  The explanation for 
these findings remains obscure; however, none of the other methods contained the same compounds or 
was as sensitive as MRM. 
 
5.5  Comprehensive screening by accurate mass measurement 
 
To be able to identify even those compounds for which primary reference standards are not readily 
available, a screening approach based on accurate mass measurement was developed.  A method for 
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Table 4. Characteristics of the MRM screening method. Data for 80 drugs commonly found in Finland 
during 2000-2003.  Therapeutic concentration ranges were collected from references 70-79.   
  Therap. conc. LOD RT [M+H]+ Fragment CE 
Compound mg/l blood mg/l min.   eV 
Caffeine 8 – 15 1.00 2.77 195.0 138.0 35 
Temazepam 0.4 - 0.9 0.02 7.18 301.0 255.0 35 
Oxazepam 0.1 - 1.4 0.02 6.33 287.0 269.0 20 
Diazepam, desmet- 0.1 -1.7 0.05 7.18 271.0 208.0 35 
Diazepam 0.1 - 2.5 0.02 8.08 285.0 222.0 35 
Paracetamol 10 – 25 5.00 2.49 152.0 110.0 20 
Citalopram 0.06 – 0.4 0.02 5.71 325.0 109.0 35 
Nicotine 0.01 - 0.04 0.05 2.15 163.2 132.0 20 
Zopiclone ad 0.1 0.10 3.96 389.0 245.0 20 
Codeine 0.03 – 0.1 0.10 2.54 300.2 215.0 35 
Levomepromazine 0.05 - 0.14 0.02 6.50 329.0 247.0 35 
Carbamazepine 5 – 10 0.02 6.10 237.0 194.0 20 
Lidocaine 2 – 5 0.05 3.73 235.2 86.0 20 
Mirtazapine (ad 0.2) 0.02 4.35 266.2 195.0 35 
Amitriptyline 0.04 - 0.2 0.02 6.56 278.0 233.0 20 
Tramadol ad 0.6 0.02 4.18 264.0 58.0 20 
Chlordiazepoxide 1- 3 0.02 5.71 300.2 282.0 35 
Demoxepam  0.02 5.82 287.0 269.0 35 
Morphine 0.08 - 0.12 0.10 1.97 286.0 201.0 35 
Citalopram, desmet-  0.02 5.53 311.2 262.0 20 
Metoprolol 0.1 - 0.6 0.02 4.07 268.2 191.0 20 
Promazine 0.1 - 0.4 0.02 6.22 285.0 86.0 20 
Doxepine 0.03 - 0.15 0.02 5.88 280.2 235.0 20 
Nortriptyline 0.05 - 0.25 0.02 6.44 264.2 233.3 20 
Fluoxetine 0.09 - 0.5 0.10 6.78 310.2 148.0 20 
Chlorprothixene 0.04 - 0.3 0.02 6.95 316.0 231.0 35 
Propranolol 0.03 - 0.25 0.02 5.37 260.2 155.0 35 
Oxycone 0.01 - 0.1 0.05 2.83 316.2 298.3 20 
Theophylline 8 – 20 5.00 2.37 181.2 124.2 20 
Olanzapine ad 0.2 0.05 2.99 313.2 256.0 35 
Warfarin 1.0 - 3.0 0.02 7.90 309.2 251.0 20 
Trimethoprim 1.5 - 2.5 0.05 3.11 291.2 230.0 35 
Thioridazine 0.2 - 1.0 0.02 7.51 371.0 126.0 35 
Diltiazem 0.05 - 0.3 0.02 5.82 415.0 178.0 35 
Venlafaxine 0.07 - 0.3 0.02 4.86 278.2 260.3 20 
Lorazepam 0.05 - 0.24 0.02 6.56 321.2 303.0 20 
Phenytoin 10 – 20 0.05 6.10 253.2 182.3 20 
Alprazolam 0.01 - 0.02 0.02 6.05 325.2 297.0 35 
Mianserine 0.03 - 0.12 0.02 5.65 265.2 208.0 20 
Dextropropoxyphen 0.1 - 0.75 0.05 6.56 340.0 266.0 20 
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Table 4 (cont.). Characteristics of the MRM screening method. Data for 80 drugs commonly found in 
Finland during 2000-2003.  Therapeutic concentration ranges were collected from references 70-79.   
  Therap. conc LOD RT [M+H]+ Fragment CE 
Compound mg/l blood mg/l min.     eV 
Metoclopramide 0.04 - 0.1 0.02 3.84 300.2 227.0 20 
Atenolol 0.2 - 0.6 0.30 1.70 267.2 225.0 20 
Clozapine 0.1 - 1.0 0.02 5.59 327.2 270.3 35 
Ketoprofen 6.0 – 14 0.10 7.28 255.0 209.0 35 
Risperidone 0.004 - 0.027 0.02 4.90 411.2 191.0 35 
Chlorpromazine 0.05 - 0.3 0.02 6.95 319.0 246.0 35 
Verapamil 0.07 - 0.35 0.02 6.50 455.2 165.0 35 
Orphenadrine 0.03 - 0.85 0.02 6.10 270.4 181.2 20 
Trimipramine 0.01 - 0.3 0.02 6.67 295.2 100.0 20 
Carbamazepine, 10-OH 2 – 30 0.10 4.52 255.2 237.0 20 
Amiloride approx. 0.04 0.10 2.03 230.2 171.0 20 
Perphenazine 0.0004 – 0.03 0.00 6.93 404.2 171.3 35 
Buprenorphine 0.5 - 10 µg/l 0.01 5.87 468.2 396.3 50 
Sertraline 0.05 - 0.25 0.02 6.78 306.0 275.2 20 
Quinine 2-8 0.02 4.24 325.2 307.0 35 
Oxcarbazepine < 1 0.02 5.31 253.2 236.0 20 
Melperone 0.04 - 0.06 0.02 5.03 264.0 165.0 35 
Moclobemide 1.5 - 2.5 0.05 3.73 269.2 182.0 20 
Triamteren 0.01 - 0.2 0.10 3.22 253.8 237.0 35 
Ranitidine 0.15 - 0.25 0.10 1.80 315.2 176.0 20 
Bisoprolol 0.01 - 0.1 0.02 4.97 326.2 116.0 20 
Tetrahydrocannabinol   0.05 12.25 315.2 193.2 20 
Indomethacine 0.7 – 4 0.05 8.58 358.0 138.8 20 
Sotalol 0.5 – 4 0.10 2.13 273.2 255.0 20 
Morphine, 6-monoacetyl-   0.10 2.65 328.2 211.0 35 
Zolpidem 0.08 - 0.15 0.02 4.69 308.2 235.3 35 
Lamotrigine 0.5 - 4.5 0.10 4.01 256.0 211.0 35 
Hydroxyzine 0.05 - 0.1 0.02 6.27 375.2 201.0 35 
Midazolam 0.08 - 0.2 0.02 5.93 326.0 291.0 35 
Paroxetine 0.008 - 0.05 0.02 6.15 330.2 192.0 35 
Fluvoxamine 0.05 - 0.25 0.02 6.33 319.2 259.0 20 
Hydroxychloroquine 0.1 - 1.0 <0.3 2.43 336.2 247.0 35 
Aminophenazone, 4-met- approx. 10 5.00 2.60 218.2 187.0 20 
Clonazepam, 7-amino-   0.02 4.35 286.2 222.0 35 
MDMA   0.02 3.28 194.2 163.0 20 
Chloroquine 0.02 - 0.5  0.02 2.65 320.0 247.0 35 
Midazolam, 1-hydroxy-   0.02 6.16 347.2 324.0 35 
Mesoridazine 0.2 - 1.6 0.02 5.37 387.2 372.3 35 
Amiodarone 0.8 - 2.8 0.05 10.22 646.0 100.3 35 
Sulpride 0.03 - 0.6 0.10 1.85 347.2 214.0 35 
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433 drugs and metabolites in urine was developed with LC–MS/TOF (V).  The mass accuracy of 5 - 10 
ppm was obtained for the majority of these drugs in authentic samples, using internal mass calibration 
with each sample. The major effort in this study was to develop postrun software to search for the 
selected masses in the total ion chromatogram (TIC), acquired as a full mass spectrum from m/z 100-
750.  For this purpose, a list of the 433 drugs selected was stored, containing the theoretical 
monoisotopic mass, RT (if known), compound name and formula, and a compound code.  Using a 
preselected mass window, this list was used for automatic generation of extracted ion chromatograms 
from the spectrum acquired, and to arrange the results so that the parent drug and its metabolites were 
reported together, which made interpretation of the results easier.  Table 5 presents an example of the 
automatic report of the results (see details in V).  Comparison of this screening method with the 
established TLC and GC methods with authentic urine samples indicated good agreement.   
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Table 5.  An example of a screening report of the results obtained with the LC–MS/TOF screening   
method.   
Code* Compound** 
Mass 
Found 
Reference 
Mass 
Ppm 
Error 
Retention 
Time 
Reference 
Retention 
Time*** 
Retention 
Time 
Error 
Peak 
Area
0153 DEMOXEPAM 287.0584 287.0582 -0.6 6.53 6.6 -0.07 8753
0154.1347 NORDIAZEPAM 271.0641 271.0633 -3 6.96 6.9 0.06 1968
0155.1344.2822 OXAZEPAM 287.0584 287.0582 -0.6 6.53 6.9 -0.37 8753
0471 FLUOXETINE 310.141 310.1408 -0.6 6.46 6.4 0.06 6836
0847 
PROMAZINE 
SULFOXIDE 301.1398 301.1369 -9.5 10.44 0  547
1666 
O-DEMETHYL 
DEACETYL 
NORDILTIAZEM 345.1223 345.1267 12.8 0.46 0  562
1666 
O-DEMETHYL 
DEACETYL 
NORDILTIAZEM 345.1227 345.1267 11.7 4.57 0  30779
1831 CODEINE 300.1601 300.1598 -1 4.89 1.3 3.59 1394
2141 PROPRANOLOL 260.162 260.1647 10.6 5.50 0  20129
2255 
10-OH-
NORTRIPTYLINE 280.1714 280.1696 -6.4 5.67 6 -0.33 474080
2431 DOXEPIN 280.1714 280.1696 -6.3 5.67 5.7 -0.03 474080
2432 NORDOXEPIN 266.1536 266.1539 1.1 5.07 5.6 -0.53 2646
2432 NORDOXEPIN 266.1547 266.1539 -2.9 5.60 5.6 0 288347
2433 DOXEPIN-N-OXIDE 296.1633 296.1645 4.1 5.18 5.2 -0.02 39720
2433 DOXEPIN-N-OXIDE 296.1639 296.1645 2 5.96 5.2 0.76 101014
2731 ZOPICLONE 389.111 389.1127 4.2 0.46 4.6 -4.14 983
2731 ZOPICLONE 389.1105 389.1127 5.6 4.57 4.6 -0.03 50133
2732 NORZOPICLONE 375.0964 375.0967 0.8 0.46 4.5 -4.04 678
2732 NORZOPICLONE 375.0981 375.0967 -3.9 4.50 4.5 0 9075
2733
ZOPICLONE- 
N-OXIDE 405.1069 405.1073 0.9 4.89 4.9 -0.01 8774
2931 HYDROCODONE 300.1601 300.1598 -1 4.89 3.1 1.79 1394
3021 NALORPHINE 312.1572 312.1596 7.5 5.35 0  9631
3131 ETHYLMORPHINE 314.1749 314.1746 -0.8 4.96 0  3858
3131 ETHYLMORPHINE 314.1686 314.1746 19.4 5.32 0  856
3441 REMOXIPRIDE 371.1008 371.0961 -12.6 11.47 0  556
3822 NORCLOBAZAM 287.0584 287.0582 -0.6 6.53 0  8753
 
* Compound Code xxyz: xx = parent drug group, y = number of compounds in the group, z = ordinal   
   number of the drug in the group 
** Correct findings underlined 
*** For those compounds without a RT in the library, a value of 0 was given. 
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6.  DISCUSSION 
 
In the present study, the scope of LC–MS was widened from target analysis to comprehensive screening 
and confirmation utilizing a library search.  In forensic toxicology, however, extraction of drugs from 
biological material is a critical step related to comprehensiveness.  Other issues that may limit the 
coverage of a screening method are chromatography, ionization, prescreening strategy, sensitivity and 
reliability of identification. 
 
Relatively good separation is needed even when MS/MS is used for detection.  Separation of analytes 
from each other and from the biological material reduces the probability of ion suppression in an ES ion 
source.  RT time was also seen to be very useful as one criterion for identification of unknowns in the 
methods developed (I, II, IV).  Detailed optimization of LC conditions and eluent composition was not 
regarded as necessary, since several studies showed that LC composition does not affect the appearance 
of MS/MS spectra.29-31,33,34  Therefore, attention was focused only on separation of analytes from the 
LC-front peak and on obtaining a reasonable compromise of total analysis time, reasonable peak shape 
and separation.  Separation of all analytes would probably not have been even possible in methods 
containing several hundreds of compounds, and therefore we attempted to use LC procedures as simple 
and general as possible.  Keeping these practical aspects in mind, we chose a commonly used column 
(RP C-18), solvent (acetonitrile) and buffer (ammonium acetate), and used a simple linear gradient 
(acetonitrile from 20% to 100% in 10 min).  The total flow was maintained at 200 µl/min to ensure 
evaporation of the eluent throughout the gradient.  Otherwise, the analytes would have remained inside 
the droplets and exited the ion source through the exhaust outlet, thereby decreasing the sensitivity.  As 
was seen in the MRM screening of 238 drugs (IV), sufficient separation was achieved under these 
general LC conditions, and the analytes were eluted quite evenly along the gradient. 
 
For the survey scan, both the SIM and MRM modes were tested and found suitable (I).  In the SIM 
mode, all compounds having the same m/z value passed the survey scan and therefore more precursor 
ions were included in the following confirmation step than in the MRM mode, in which the fragment 
ions were also defined in advance.  Preselection of the precursor and fragment ions limits the coverage 
of the survey scan, but on the other hand makes the survey scan much more selective and sensitive than 
using the full scan.  As a new point of view, it could be possible to perform the survey scan with a step 
size of 1.0 Da instead of the commonly used 0.1 Da, and thereby select all total mass values within the 
mass range of interest, e.g. m/z 150-700 for toxicologically relevant drugs and by that means cover the 
entire mass range.  This approach has not been studied in practice, but it could be as “general” as using 
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a full scan for the screening step44 and probably would be more sensitive.  Whatever survey scan is 
used, the confirmation step should be based on product ion spectra searched against a spectral library.  
For β-blocking drugs, the survey scan with SIM was selected due to its simplicity, whereas MRM 
provided the simultaneous quantitation needed in the antihistamine analysis.  Currently however, MRM 
is applied to all LC-MS screening and quantitation analyses, due to its better selectivity and sensitivity.  
The methods for antihistamine and β-blocking drugs are in routine use with the exception that the 
confirmation step could not yet be automated after the change in software from the MacIntosh-based 
Multiview 1.4 to MS Windows-based Analyst 1.3. 
 
Triple-quadrupole mass spectrometers have widely been used for quantitative analysis because of their 
high selectivity and sensitivity combined with good reproducibility.  The special challenge for 
quantitation of drugs in forensic samples is that the difference between low therapeutic and lethal 
concentrations can be as much as 1000-fold.  During validation of the antihistamine method (II), it was 
noted that the calibration curves were not linear over a very broad range of concentrations (0.05-500 
µg/l.  This is typically encountered in quantitation with LC–MS/MS/MRM and was also reported by 
others.59 Therefore, the calibration points and regression were chosen according to relevant 
concentration ranges.  Bending of the calibration curves was first suspected to be due to ion suppression 
caused by the matrix, which was claimed to be a serious problem in LC–MS for quantitation of drugs in 
forensic samples where the matrix varies remarkably from one sample to another.80  However, our 
spiking tests of antihistamines in several autopsy samples revealed only slightly higher RSDs between 
samples than within samples, which in our opinion showed that matrix-related ion suppression did not 
affect this analysis. However, the limited dynamic range was more likely due to suppression of the 
analyte itself in high concentrations. Our observations were in agreement with other ion-suppression 
studies,69,81 which demonstrated that matrix-related ion suppression is more pronounced in the LC-front 
peak than in the rest of the gradient, where the analytes are separated from the polar and unretained 
components of the matrix. 
 
Various strategies for combined screening and confirmation of drugs were examined: single-MS using 
SIM for the survey scan and in-source CID spectra or MS/MS product ion spectra for confirmation, 
MS/MS using MRM for the survey scan and MS/MS product ion spectra for confirmation, and LC–
MS/TOF using accurate masses for the survey scan and confirmation.   The single quadrupole 
instrument is a suitable and nonexpensive choice for screening.  Moreover, the LC–MS/in-source CID 
spectra, being summed low- (+25 V) and high-orifice voltage (+90 V) spectra, contained both fragment 
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ions and an intensive protonated molecule, which was usually weak or totally missing from the LC–
MS/MS product ion spectra at medium or high collision energy levels.  Various combinations of low 
and high voltages were used by others, e.g. +20, +50 and +80 V,29 ± 20 V and ± 80 V,30 ± 10 V, ± 50 V 
and ±100 V,31 or even linear ramping of the voltage,33 but in general, for relevant information only two 
different levels are needed.  The presence of the protonated molecule in the spectrum is an undeniable 
benefit against LC–MS/MS spectra, which were more specific because the only origin of the fragments 
was the precursor ion chosen.  More harmony has been shown in the selection of collision energies in 
MS/MS.  In addition to our choice of using 20, 35 or 50 eV, only a combination of 20, 30, 40 and 50 eV 
was applied.40  We observed that still higher or lower collision energies added no new information to 
the product ion spectra.  As can be concluded from the diversity of the applications, it is reasonable and 
indispensable to standardize the fragmentation conditions if library searches are commonly and 
routinely to be used for identification.  In contrast, it is always beneficial to optimize relevant 
fragmentation conditions to obtain the highest sensitivity for quantitation purposes. 
 
The possibility of creating and using universal LC–MS/MS spectral libraries was evaluated.   Before 
universal LC–MS/in-source CID and LC–MS/MS spectral libraries can be created and used, agreement 
should be reached on the fragmentation conditions to be employed, but to date this has not been done, 
as previously discussed.  To determine whether there is a basis at all to usage of spectral libraries, 
reproducibility of LC–MS/MS product ion spectra within one and between separate triple-quadrupole 
mass spectrometers was examined. Long-term reproducibility within instruments was excellent and in 
agreement with previous studies,40 which encouraged further testing for similarity of spectra obtained 
with similar instruments from the same and from different manufacturers.  The results showed that LC–
MS/MS spectra, acquired with one instrument, can successfully be searched against a library created 
with another instrument of the same type.  This is a promising finding for future efforts to develop 
generally available LC–MS/MS spectral libraries, and warrants further comparison with other 
instruments and manufacturers. 
 
Comparison between spectra is difficult when instruments use different software programs that are not 
compatible.  We also observed that algorithms for data processing prior to the library search were not 
similar and altered the data in different ways, leading to unacceptable library search results.  For 
instance, one software used centroiding parameters that deleted important small peaks, such as those for 
the protonated molecules.  During the library search process itself, the intensity factor was also seen to 
affect the search results.  In contrast to previous opinions,30,35 judgment on similarity should include 
tight criteria for peak intensity ratios, at least when conclusions are drawn on the performance of 
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instruments.  Mass spectra are generally used for identification of unknown compounds, and the criteria 
for positive identification have been discussed in many contexts.  However, there still is no common 
agreement on the acceptance criteria for a reliable match, although suggestions of approximately 70-
80% were presented for a fair or good match.33,34  According to studies on the subject and our previous 
experience with actual samples, we suggest that a Fit of approximately 70% or higher would result in a 
satisfactory confidence level, presuming that the peak intensity would allow the entire spectrum to be 
detected.   
 
Comprehensive screening with MRM (IV) was also tested and was found to be sensitive and reliable for 
a large number of compounds.  Some important factors demanded special attention: cross-talk, which 
may occur if two compounds co-elute and have the same fragment ions, instrument scanning speed, 
which limited the number of compounds that were detected during a single chromatographic run and 
dwell time, which effected sensitivity and also limited the number of compounds.  Cross-talk is a 
known feature of older triple-quadrupole models, but can be avoided by careful planning of the order of 
MRM transitions, as was demonstrated earlier.56 Scanning speed and the applied dwell time together 
contributed to the sensitivity.  Increasing the dwell time to promote sensitivity led to fewer data points 
across the chromatographic peak and thereby made detection insecure.  However, instrumental 
technology has improved rapidly, and at present dwell times as low as 5 ms can be used.    According to 
the generally accepted rules for reliable identification,82 the number of MRM transitions should be at 
least two, providing a total of three diagnostic ions.  With the additional criterion for RT, these 
parameters provide a high confidence level in both screening and quantitation.  The method developed 
could easily have been expanded to also include confirmatory ions, but the available instrument 
scanning speed was decisive and determined the number of transitions that could be monitored during a 
single run.  However, the method developed with 238 transitions is the broadest published screening 
application of MRM available. 
 
One way to enlarge the coverage of the method is to split the chromatographic run into time windows, 
as was proposed for multicomponent screening with GC.54  By this means, fewer transitions are 
monitored at the same time, and therefore higher dwell times can be used to improve sensitivity or the 
number of compounds searched can be increased.   Sensitivity can also be improved by optimizing the 
collision energy for every compound individually.59  Optimization was not performed for the 238 
compounds in our method, because the intention was to use standard operating conditions in all LC–
MS/MS work in the laboratory.  Even so, the sensitivity obtained in the MRM screening method 
developed was sufficiently high for routine studies of forensic samples.   
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In the comprehensive screening method using LC–MS/TOF (V), no separate prescreening step was 
needed, while during acquisition the instrument recorded all masses at the selected mass range.  Using 
this feature, TOF instruments enable a basically unlimited number of toxicants to be screened during a 
single injection without sacrificing the sensitivity or selectivity.  One limitation, set by the user, was the 
selection of compounds on the target list, which was limited to 433 common drugs and their 
metabolites.   Some complexity in interpretation of the results was also caused by the fact that two or 
even more drugs were obtained for the same molecular formula.  The number of candidates differing by 
formula can be further decreased by using an instrument with higher mass accuracy, or using RT as an 
identification criterion.  RTs were not used in the automatic procedure, because they were not known 
for most of the metabolites. However, the metabolic pattern was an efficient tool for ruling out apparent 
false-positive findings.  Automatic processing was absolutely necessary in this method, because 
substantial information was extracted from huge amounts of data.  Nonautomatic methods cannot be 
accepted for routine analysis when large numbers of samples are to be analysed daily.  Automation also 
decreases the possibility of human errors.  Special programs were also needed for the other methods 
developed, because the original software did not contain the necessary options for data handling and 
convenient reporting.   
 
RTs of metabolites can be collected from routine samples containing parent drugs and their metabolites, 
and these data were later added to the identification criteria in the improved version of the method,83 
which has been taken into routine use and accredited by the Finnish Accreditation Service (FINAS) in 
June 2004. The possibility of detecting toxicants without reference compounds is a major advantage of 
this approach.  In forensic toxicology, maintaining a large selection of reference compounds is very 
expensive and even impossible, because most of the metabolites are not commercially available.  
Therefore, LC–MS/TOF appears to be very suitable for this type of application, and this technique was 
considered as the closest approach to the so-called “general unknown screening”, especially if high-
resolution instruments were used.  
 
Both screening methods, LC-MS/MS/MRM (IV) and LC-MS/TOF (V), are suitable for routine use in 
forensic studies.  Screening of real unknowns is not possible with the MRM technique, but from the 
practical point of view, the selection of compounds routinely found in post mortem forensic 
toxicological cases may not be very wide.  For example, in the Forensic Toxicology Laboratory of the 
University of Helsinki between 2000 and 2003, approximately 90 of 300 compounds found covered 
95% of all findings.  Therefore, the choice of method can be done according to the instrumentation 
available and screening strategy preferred. 
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7.  CONCLUSIONS  
 
This dissertation described novel approaches for expanding the limits of LC–MS from conventional 
target analysis of a few compounds to comprehensive analysis based on large spectral libraries. The 
challenges originated from drug screening and confirmation problems encountered in forensic and 
clinical toxicology.  The strengths of LC–MS over other techniques were the broad range of compounds 
that could be analysed and the ruggedness of instrumentation against difficult sample matrices. 
 
Triple-quadrupole MS/MS proved to be a selective and sensitive technique for identification based on 
library searching of product ion spectra.  Two automated procedures demonstrated the advantages of the 
technique. SIM and MRM were applied to the qualitative analysis of β-blocking drugs in urine and 
quantitative analysis of antihistamines in blood, respectively, with confirmation by product ion spectra 
against an in-house library of 400 drugs. The quantitation method of antihistamines also showed that 
with MRM techniques, compounds at very low concentration can be quantitated accurately from 
forensic samples containing high background. 
 
The in-house library of product ion spectra of 400 drugs was shown to be reproducible in the long term. 
Moreover, spectral libraries created with identical instruments from the same manufacturer, were fully 
compatible.  The finding that the spectra obtained using a different manufacturer’s instruments under 
standardized conditions could also be successfully searched against the in-house library widens the 
prospect for the generation of universal spectral libraries. The future of LC-MS/MS libraries will be 
dependent not only on the activity of LC-MS/MS users but also on that of the manufacturers, who play 
an important role in developing the instrument software.  To date, there has been little interest among 
manufacturers to develop or financially support work on universal LC-MS/MS spectral libraries; 
however, this may well change along with the novel studies.  
 
The largest target-screening method published using MRM included transitions for 238 drugs, and the 
method was also amenable to simultaneous quantification. The LODs in blood were generally at 
therapeutic levels, suggesting the method was sufficiently sensitive for use in forensic contexts. 
  
LC–MS/TOF provided a screening method for drugs and metabolites without reference standards, and a 
target database for 433 compounds was created.  A mass accuracy of 20 ppm obtained in real urine 
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samples together with the metabolic pattern obtained were suggested to be sufficient to detect the 
correct findings and to rule out apparent false-positive findings, with the use of dedicated software.  
 
The methods described persuaded us that LC-MS is very suitable for a variety of applications in 
forensic toxicology, in which high reliability of results is categorical.  Screening of a wide variety of 
compounds and quantitation of a wide range of concentrations from a diverse matrix is a demanding 
task, but LC-MS proved to be amenable to such applications.  However, no single technique alone is 
sufficient to attain the expected confidence level and therefore LC-MS, adequate as it is, cannot replace 
all other techniques, but will be used together with those recognized to be useful and effective. 
 
  47 
 
AKNOWLEDGEMENTS 
 
This study was carried out at the Department of Forensic Medicine, University of Helsinki, during the 
years 1999-2004.    
 
I especially acknowledge Prof. Erkki Vuori, Head of the Forensic Chemistry Division, for his firm 
support and his willingness to offer a stimulating environment and equipment for my studies. I also 
appreciate his encouraging comments and the great interest he has shown in my work during these 
years.  I also recognize the importance of the support and encouragement offered by Prof. Reija Jokela, 
Professor of Organic Chemistry in the Helsinki University of Technology, not only during the process 
of this thesis but also during my previous studies at the University of Technology. 
 
I am very grateful to my first supervisor Dr. John Robson, who initially guided my enthusiasm to work 
with LC–MS and provided his expertise for realizing the broad range of new ideas, and who also 
managed the cooperation with the instrument manufacturer.  I also greatly appreciate my second 
supervisor Docent Ilkka Ojanperä for stimulating discussions and his patience in helping me to 
transform my tangled manuscripts into scientific articles.  My special thanks to Pirjo Tiainen for her 
skilful laboratory assistance during the experimental work.  The entire staff of the Laboratory of 
Forensic Toxicology deserves my warmest compliments by being most helpful and cooperative, and by 
providing educated guesses for solving a few of the so-called  ‘challenges’.   
 
I also thank my good friends, who have been my cheerleaders, always encouraging me without second 
thoughts (even when they should have) in whatever I have done in my life - and especially in the last 
few months during those desperate moments when I was just about ready to give up on this thesis.   
 
Finally, and most warmly, I thank my family for their never-ending belief in me.    
 
Financial support from Consolidated Research Incorporated (Los Angeles, CA, USA) is gratefully 
acknowledged. 
  48 
 
REFERENCES  
         
1. Drummer, O.H., Chromatographic screening techniques in systematic toxicological analysis, J. 
Chromatogr. B 733 (1999) 27-45. 
 
2.  Polettini, A., Systematic toxicological analysis of drugs and poisons in biosamples by hyphenated 
chromatographic and spectroscopic techniques, J. Chromatogr. B 733 (1999) 47-63. 
 
3.  deZeeuw, R.A., Franke, J.P., “General unknown” analysis, in Handbook of Analytical 
Separations, ed. Smith, R.M., Elsevier, Amsterdam 2000, 567-599. 
 
4.  Cosbey, S.H., Craig, I., Gill, R., Novel solid-phase extraction strategy for the isolation of basic 
drugs from whole blood. Preliminary study using commercially available extraction cartridges, J. 
Chromatogr. B: Biomedical Applications 669 (1995) 229-235. 
 
5.  Yawney, J., Treacy, S., Hindmarsh, K.W., Burczynski, F.J., A general screening method for 
acidic, neutral, and basic drugs in whole blood using the Oasis MCX column, J. Anal. Toxicol. 26 
(2002) 325-332. 
 
6.  Chen, X.-H., Franke, J.P., Wijspeek, J., deZeeuw, R.A., Isolation of acidic, neutral and basic 
drugs from whole blood using a single mixed mode solid-phase extraction column, J. Anal. 
Toxicol. 16 (1992) 351-355. 
 
7.  Chen, X.H., Franke, J.P., Ensing, K., Wijsbeek, J., deZeeuw, R.A., Pitfals and solutions in the 
development of a fully automated solid-phase extraction method for drug screening purposes in 
plasma and whole blood, J. Anal. Toxicol. 17 (1993) 471-476. 
 
8.  Chen, X.H., Franke, J.P., Ensing, K., deZeeuw, R.A., Study of lot-to-lot reproducibilities of Bond 
Elute Certify and Clean Screen DAU mixed-mode solid-phase extraction columns in the 
extraction of drugs from whole blood, J. Chromatogr. B: Biomedical Applications 617 (1993) 
147-51. 
 
9.  Cox, R.A., Crifasi, J.A., Dickey, R.E., Ketzler, S.C., Pshak, G.L., A single-step extraction for 
screening whole blood for basic drugs by capillary GC/NPD, J. Anal. Toxicol. 13 (1989) 224-228. 
  49 
 
10.  Hoja, H., Marquet, P., Verneuil, B., Lotfi, H., Pénicaut, B., Lachâtre, G., Applications of liquid 
chromatography–mass spectrometry in analytical toxicology: A review, J. Anal. Toxicol. 21 
(1997) 116–124.  
 
11.  Maurer, H.H., Liquid chromatography–mass spectrometry in forensic and clinical toxicology, J. 
Chromatogr. B 713 (1998) 3-25.      
 
12.  Marquet, P., Lachâtre, G., Liquid chromatography–mass spectrometry: potential in forensic and 
clinical toxicology, J. Chromatogr. B 733 (1999) 93-118. 
 
13.  Bogusz, M.J., Hyphenated liquid chromatographic techniques in forensic toxicology, J. 
Chromatogr. B 733 (1999) 65-91. 
 
14.  Van Bocxlaer, J.F., Clauwaert, K.M., Lambert, W.E., Deforce, D.L., Van den Eeckhout, E.G., De 
Leenheer, A.P., Liquid chromatography–mass spectrometry in forensic toxicology, Mass 
Spectrometry Reviews 19 (2000) 165-214.                                                                                                     
 
15.  Marquet, P., Is LC–MS suitable for a comprehensive screening of drugs and poisons in clinical 
toxicology, Therapeutic Drug Monitoring, 24 (2002) 125-133.                                    
 
16.  Marquet, P., Progress of liquid chromatography–mass spectrometry in clinical and forensic 
toxicology, Therapeutic Drug Monitoring, 24 (2002) 255-276. 
 
17. Zeleny, J., Instability of electrified liquid surfaces, Phys. Rev. 10 (1917) 1-6. 
 
18. Dole, M., Mack, L.L., Hines, R.L., Mobley, R.C., Ferguson, L.D., Alice, M.B., Molecular beams 
of macroions, J. Chem. Phys. 49 (1968) 2240-2249.  
 
19. Tal’Rose, V.L., Grishen, V.D., Skurat, V.E., Tantsyrev, G.D., Recent developments in mass 
spectroscopy, Ed. Ogata, K., Hayakawa T., University Park Press, Baltimore 1970.                         
 
20. Horning, E.C., Horning, M.G., Carroll, D.I., Dzidic, I., Stillwell, R.N., New pictogram detection 
system based on a mass spectrometer with an external ionization source at atmospheric pressure, 
Anal. Chem. 45 (1973) 936-943.  
  50 
 
 
21. Arpino, P.J., Baldwin, M.A., McLafferty, F.W., Liquid chromatography–mass spectrometry. II. 
Continuous monitoring, Biomed. Mass Spectrom 1 (1974) 80-82. 
 
22. Arpino, P.J., Dawkins, B.G., McLafferty, F.W., A liquid chromatography/mass spectrometry 
system providing continuous monitoring with nanogram sensitivity, J. Chromatogr. Sci 12 (1974) 
574-578. 
 
23.  Iribarne, I.V., Thomson, B.A., On the evaporation of small ions from charged droplets, J. Chem. 
Phys. 64 (1976) 2287-2294. 
 
24. Yamashita, M., Fenn, J.B., Electrospray ion source. Another variation on the free-jet theme, Phys. 
Chem. 88 (1984) 4451-4459. 
 
25. Robb, D.B., Covey, T.R., Bruins, A.P.,   Atmospheric pressure photoionization: an ionization 
method for liquid chromatography–mass spectrometry, Anal. Chem. 72 (2000) 3653-3659. 
 
26. Bruins, A.P., Covey T.R., Henion, J.D., Ion spray interface for combined liquid 
chromatography/atmospheric pressure ionization mass spectrometry, Anal. Chem. 58 (1987) 2647-
2646. 
 
27.  Schmelzeisen-Redeker, G., Bütfering, L., Röllgen, F.W., Desolvation of ions and molecules in 
thermospray mass spectrometry, Int. J. Mass Spectrom. Ion Processes 90 (1989) 139-150.      
 
28. Hopfgartner, G., Bean, K., Henion, J., Henry, R., Ion spray mass spectrometric detection for liquid 
chromatography: a concentration- or a mass-flow-sensitive device?, J. Chromatogr. 647 (1993) 
51-61. 
 
29.  Weinmann, W., Wiedemann, A., Eppinger, B., Renz, M., Svoboda, M., Screening for drugs in 
serum by electrospray ionization/collision-induced dissociation and library searching,  J. Am. Soc. 
Mass Spectrom. 10 (1999) 1028-1037. 
 
30.  Marquet, P., Venisse, N., Lacassie, N., Lachâtre, G., In-source CID mass spectral libraries for the 
“general unknown” screening of drugs and toxicants, Analusis 28 (2000) 925-937. 
  51 
 
31.  Schreiber, A., Efer, J., Engewald, W., Application of spectral libraries for high-performance liquid 
chromatography–atmospheric pressure ionisation mass spectrometry to the analysis of pesticide 
and explosive residues in environmental samples, J. Chromatogr. A 869 (2000) 411-475. 
 
32. Bogusz, M.J., Maier, R-D., Krüger, K.D., Webb, K.S., Romeril, J., Miller, M.L., Poor 
reproducibility of in-source collisional atmospheric pressure ionization mass spectra of 
toxicologically relevant drugs, J. Chromatogr. A 844 (1999) 409-418.  
 
33.  Lips, A.G.A.M., Lameier, W., Fokkens, R.H., Nibbering, N.M.M., Methodology for the 
development of a drug library based upon collision-induced fragmentation for the identification of 
toxicologically relevant drugs in plasma samples, J. Chromatogr. B 759 (2001) 191-207. 
 
34.  Hough, J.M., Haney, C.A., Voyksner, R.D., Bereman, R.D., Evaluation of electrospray transport 
CID for the generation of searchable libraries, Anal. Chem. 72 (2000) 2265-2270. 
 
35.  Weinmann, W., Stoertzel, M., Vogt, S., Wendt, J., Tune compounds for electrospray ionisation/in-
source collision-induced dissociation with mass spectral library searching, J. Chromatogr. A 926 
(2001) 199-209. 
 
36.  Weinmann, W., Stoertzel, M., Vogt, S., Svoboda, M., Schreiber, A., Tuning compounds for 
electrospray ionization/in-source collision-induced dissociation and mass spectral library 
searching, J. Mass Spectrom.  36 (2001) 1013-1023. 
              
37.  Bristow, A.W.T., Nichols, W.F., Webb, K.S., Conway, B., Evaluation of protocols for 
reproducible electrospray in-source collisionally induced dissociation on various liquid 
chromatography/mass spectrometry instruments and the development of spectral libraries, Rapid 
Commun. Mass Spectrom. 16 (2002) 2374-2386. 
 
38.  Dawson, P.H., Sun, W-F., A Round Robin on the reproducibility of standard operation conditions 
for the acquisition of library MS/MS spectra using triple quadrupoles, Int. J. Mass Spectrom. Ion 
Processes 55 (1983/1984) 155-170. 
 
  52 
 
39.  Martinez, R.I., Standard reference spectra for tandem mass spectrometry quality assurance, 
performance evaluation and proficiency testing: tandem mass spectrometers which use RF-only 
multipole collision cells, Rapid Commun. Mass Spectrom. 5 (1991) 245-248.              
 
40.  Weinmann, W., Gergov, M., Goerner, M., MS/MS libraries with triple quadrupole-tandem mass 
spectrometers for drug identification and drug screening, Analusis 28 (2000) 934-941.    
                                  
41.  Kienhuis, P.G.M., Geerdink, R.B., Liquid chromatography–tandem mass spectrometric analysis of 
surface and waste water with atmospheric pressure chemical ionization. II. Applications. Trends 
Anal. Chem. 19 (2000) 460-474. 
 
42.  Kienhuis, P.G.M., Geerdink, R.B., A mass spectral library based on chemical ionization and 
collision-induced dissociation, J. Chromatogr. A 974 (2002) 161-168.  
 
43. Josephs, J.L., Characterization of over-the-counter cough/cold medications by liquid 
chromatography/electrospray mass spectrometry, Rapid Commun. Mass Spectrom. 9 (1995) 1270-
1274. 
 
44.  Marquet, P., Dupyi J.L., Lachâtre, G., Shushan, B., Duchoslav, E., Monasterios, C., Ilisieu, P., 
Anacleto, J., Development of a “General Unknown” screening procedure using liquid 
chromatography–electrospray-mass spectrometry (LC–EC-MS), in: Proc. 46th ASMS Conference 
on Mass Spectrometry and Allied Topics 1998, Orlando, FL, 1998. 
 
45.  Slobodnik, J., Hogenboom, A.C., Vreuls, J.J., Rontree, J.A., van Baar, B.L.M., Niessen, W.M.A., 
Brinkman, U.A.Th., Trace-level determination of pesticide residues using on-line solid-phase 
extraction-column liquid chromatography with atmospheric pressure ionization mass 
spectrometric and tandem mass spectrometric detection, J. Chromatogr. A 741(1996) 59-74. 
 
46.  Sander, P., Substance identification of ion trap MS/MS spectra in a MS/MS library, in: Proc. 47th 
ASMS Conference on Mass Spectrometry and Allied Topics 1999, Dallas, TX, 2000.   
 
47.  Fitzgerald, R.L., Rivera, J.D., Herold, D.A., Broad spectrum drug identification directly from 
urine, using liquid chromatography–tandem mass spectrometry, Clinical Chemistry 45 (1999) 
1224-1234.   
  53 
 
48.  Sanders, M., Josephs, J., Schwartz, J., Tymiak, A., DiDonato, G., Rapid identification of natural 
products using a modified ion trap mass spectrometer and MS/MS spectral library searching, in: 
Proc. 47th ASMS Conference on Mass Spectrometry and Allied Topics 1999, Dallas, TX, 2000.   
 
49.   Baumann, C., Cintore, M.A., Eichler, M., Lifante, E., Cooke, M., Przyborowska, A., Halket, J.M., 
A library of atmospheric pressure ionization daughter ion mass spectra based on wideband 
excitation in an ion trap mass spectrometer, Rapid Commun. Mass Spectrom. 14 (2000) 349-356. 
 
50.  Schreiber A., Gergov, M., Weinmann, W., Transfer of existing forensic LC/MS and LC/MS/MS 
mass spectral libraries to linear ion trap instrumentation, in: Poster 52th ASMS Conference on 
Mass Spectrometry and Allied Topics 2004, Nashville, TN, 2004. 
 
51.  Saint-Marcoux, F., Lachâtre, G., Marquet, P., Evaluation of an improved general unknown 
screening procedure using liquid chromatography–electrospray-mass spectrometry by comparison 
with gas chromatography and high-performance liquid chromatography-diode array detection,  J. 
Am. Soc. Mass Spectrom. 14 (2003) 14-22. 
 
52.  Rittner, M., Pragst, F., Bork, W.-R., Neumann, J., Screening method for seventy psychoactive 
drugs or drug metabolites in serum based on high-performance liquid chromatography–
electrospray ionization mass spectrometry, J. Anal. Toxicol. 25 (2001) 115-124.                                           
 
53.  Venisse, N., Marquet, P., Duchoslav, E., Dupuy, J.L., Lachâtre, G., A general unknown screening 
procedure for drugs and toxic compounds in serum using liquid chromatography–electrospray-
single quadrupole mass spectrometry, J. Anal. Toxicol. 27 (2003) 7-14. 
 
54.  Fillion, J., Hindle, R., Lacroix, M., Selwyn, J., Multiresidue determination of pesticides in fruit 
and vegetables by gas chromatography–mass selective detection and liquid chromatography with 
fluorescence detection, J. AOAC Int.78 (1995) 1252-1266. 
 
55.  Heinig, K., Henion J., Fast liquid chromatographic–mass spectrometric determination of 
pharmaceutical compounds, J. Chromatogr. B 732 (1999) 445-458.  
 
  54 
 
56.  Tong, X., Ita, I.E., Wang, J., Pivnichny, J.V., Characterization of a technique for rapid 
pharmacokinetic studies on multiple co-eluting compounds by LC/MS/MS, J. Pharm. Biomed. 
Anal. 20 (1999) 773–784. 
 
57.  Thieme, D., Grosse, J., Lang, R., Mueller, R.K., Wahl, A., Screening, confirmation and 
quantitation of diuretics in urine for doping control analyses by high-performance liquid 
chromatography–atmospheric pressure ionization tandem mass spectrometry, J. Chromatogr. B 
757 (2001) 49–57.                   
 
58.  Thieme, D., Sachs, H., Improved screening capabilities in forensic toxicology by application of 
liquid chromatography–tandem mass spectrometry, Anal. Chim. Acta 492 (2003) 171-186. 
 
59.  Josefsson, M., Kronstrand, R., Andersson, J., Romas, M., Evaluation of electrospray ionization 
liquid chromatography–tandem mass spectrometry for rational determination of a number of 
neuroleptics and their metabolites in human body fluids and tissues, J. Chromatogr. B 789 (2003) 
151-167. 
 
60.  Jemal, M., Ouyang, Z., Zhao, W., Zhu, M., Wu, W.W., A strategy for metabolite identification 
using triple-quadrupole mass spectrometry with enhanced resolution and accurate mass capability, 
Rapid Commun. Mass Spectrom. 17 (2003) 2732–2740.                                                                         
 
61.  Zhang, N., Fountain, S.T., Bi, H., Rossi, D.T., Quantification and rapid metabolite identification 
in drug discovery using API time-of-flight LC/MS, Anal. Chem. 72 (2000) 800-806.                                    
 
62.  Zhang, H., Henion, J., Yang, Y., Spooner, N., Application of atmospheric pressure ionization 
time-of-flight mass spectrometry coupled with liquid chromatography for the characterization of 
in vitro drug metabolites, Anal. Chem. 72 (2000) 3347-3348.                                                              
 
63.  Zhang, H., Heinig, K., Henion, J., Atmospheric pressure ionization time-of-flight mass 
spectrometry coupled with fast liquid chromatography for quantitation and accurate mass 
measurement of five pharmaceutical drugs in human plasma, J. Mass Spectrom. 35 (2000) 473-
431.                 
 
  55 
 
64.  Hopfgartner, G., Chernushevich, I.V., Covey, T., Plomley, B., Bonner, R., Exact mass 
measurement of product ions for the structural elucidation of drug metabolites with a tandem 
quadrupole orthogonal-acceleration time-of-flight mass spectrometer, J. Am. Soc. Mass Spectrom. 
10 (1999) 1305-1314.  
 
65.  Decaestecker, T.N., Clauwaert, K.M., Van Bocxlaer, J.F., Lambert, W.E., Van den Eeckhout, 
E.G., Van Peteghem C.H., De Leenheer, A.P., Evaluation of automated single mass spectrometry 
to tandem mass spectrometry function switching for comprehensive drug profiling analysis using 
a quadrupole time-of-flight mass spectrometer, Rapid Commun. Mass Spectrom. 14 (2000) 1787-
1792.  
 
66.  Bobeldijk, I., Vissers, J.P.C., Kearney, G., Major, H., van Leerdam, J.A., Screening and 
identification of unknown contaminants in water with liquid chromatography and quadrupole-
orthogonal acceleration-time-of-flight tandem mass spectrometry, J. Chromatogr. A 929 (2001) 
63-74.  
 
67. King, R., Bonfiglio, R., Fernandez-Mezler, C., Miller-Stein, C., Olah, T., Mechanistic 
investigation of ionization suppression in electrospray ionization, J. Am. Soc. Spectrom. 11 (2000) 
947-950. 
 
68.  Marquet, P., Saint-Marcoux, F., Camble, T.N., Leblanc J.C.Y., Comparison of preliminary 
procedure for the general unknown screening of drugs and toxic compounds using quadrupole-
linear ion-trap mass spectrometer with liquid chromatography–mass spectrometry reference 
technique, J. Chromatogr. B 789 (2003) 9-18. 
      
69.  Müller, C., Schäfer, P., Störtzel, M., Vogt, S., Weinmann, W.,  Ion suppression effects in liquid 
chromatography–electrospray ionization transport-region collision induced dissociation mass 
spectrometry with different extraction methods for systematic toxicological analysis with mass 
spectral libraries, J. Chromatogr. B 733 (2002) 47-52.                                                            
 
70.  Clarke's Isolation and Identification of Drugs, 2.p., Ed. Moffat, A.C., The Pharmaceutical Press, 
London 1986. 
 
 
  56 
 
71.   Osselton, M.D., Toxicological tables: a compendium of pharmacological, therapeutic and 
toxicological data on 136 drugs and chemicals on humans, Bull. Int. Assoc. Forens. Toxicol. 17 
(1983) 16-33. 
 
72.  Stead, A.H., Moffat, A.C., A collection of therapeutic, toxic and fatal blood drug concentrations in 
man, Human Toxicol. 3 (1983) 437-464. 
 
73.  Pandurangi, A.K., Narasimhachari, N., Blackard, W.G., Landa, B.S., Relation of serum molindone 
levels to serum prolactin levels and antipsychotic response,  J. Clin. Psych. 50 (1989) 379-381. 
 
74.   Jack, D.B., Handbook of Clinical Pharmacokinetic Data. Macmillan, Hants 1992. 
 
75.   Klamerus, K.J., Maloney, K., Rudolph, R.L., Sisenwine, S.F., Jusko, W.J., Chiang, S.T., 
Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-
desmethyl metabolite,  J. Clin. Pharmacol. 32 (1992) 716-724. 
 
76.   Meyer, F.P., Indicative therapeutic and toxic drug concentrations in plasma: a tabulation, Int. J. 
Clin. Pharm. Ther. 32 (1994) 71-81. 
 
77.  Uges, D.R.A., Therapeutic and toxic drug concentrations, Bull. Int. Assoc. Forens. Toxicol. 26 
(1996) (1 supplement) 1-34. 
 
78.  Schulz, M., Schmoldt, A., Therapeutic and toxic blood concentrations of more than 500 drugs, 
Pharmazie 52 (1997) 895-911. 
 
79.  Winek, C.L., Wahba, W.W., Winek Jr., C.L., Winek-Balzer, T., Drug and chemical blood-level 
data 2001, Forensic Sci. Int. 122 (2001) 107-123. 
 
80.   Maurer, H.H., Schmitt, C.J., Weber, A.A., Kraemer, T., Validated electrospray liquid 
chromatographic–mass spectrometric assay for the determination of the mushroom toxins alpha- 
and beta-amanitin in urine after immunoaffinity extraction.    J. Chromatogr. B 748 (2000) 125-
135.      
 
  57 
 
81.  Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M., Matrix effects in quantitative 
LC/MS/MS analyses of biological fluids: A method for determination of finasteride in human 
plasma at picogram per milliliter concentrations, Anal. Chem. 70 (1998) 882-889. 
 
82.  Rivier, L., Criteria for the identification of compounds by liquid chromatography–mass 
spectrometry and liquid chromatography–multiple mass spectrometry in forensic toxicology and 
doping analysis, Anal. Chim. Acta 492 (2003) 69-82.   
 
83.  Pelander, A., Ojanperä, I., Laks, S., Rasanen, I., Vuori, E., Toxicological screening with formula-
based metabolite identification by liquid chromatography/time-of-flight mass spectrometry, Anal. 
Chem. 75 (2003) 5710-5718. 
 
 
